Jennifer Klemmer

Anti-SARS-CoV-2 antibody-containing plasma improves outcome in patients with hematologic or solid cancer and severe COVID-19: a randomized clinical trial

Claudia M. Denkinger, Maike Janssen, Ulrike Schäkel et al. · Nature Cancer · 2022 · 62 citations · Full text

Veterinary Medicine, Immunology, Oncology +17

Rituximab maintenance improves survival in male patients with diffuse large B-cell lymphoma. Results of the HD2002 prospective multicentre randomized phase III trial

Mathias Witzens‐Harig, Axel Benner, Fabienne McClanahan et al. · British Journal of Haematology · 2015 · 37 citations · Full text

Medicine, Hematology, Oncology +12

First Results of a Phase-II Study with the New CXCR4 Antagonist POL6326 to Mobilize Hematopoietic Stem Cells (HSC) In Multiple Myeloma (MM)

Stefan Schmitt, Niels Weinhold, Klaus Dembowsky et al. · Blood · 2010 · 26 citations

Medicine, Hematology, Pharmacology +17

Safety and efficacy of the CD95-ligand inhibitor asunercept in transfusion-dependent patients with low and intermediate risk MDS

Tobias Boch, Thomas Luft, Georgia Metzgeroth et al. · Leukemia Research · 2018 · 15 citations

Medicine, Pharmacology, Pharmacotherapy +11

The mTOR Inhibitor Temsirolimus Added to Rituximab Combined With Dexamethasone, Cytarabine, and Cisplatinum (R-DHAP) for the Treatment of Patients With Relapsed or Refractory DLBCL – Results From the Phase-II STORM Trial

Mathias Witzens‐Harig, Andreas Viardot, Ulrich Keller et al. · HemaSphere · 2021 · 10 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +14